Clinical Trial

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-11-12; most recent amendment 2026-05-11.
Status change: Not Yet Recruiting → Recruiting 2025-04-09
Trial Details
NCT Number NCT05133882
Lead Sponsor Sunshine Lake Pharma Co., Ltd.
Conditions Acute Myeloid Leukemia, Adult
Enrollment 133 participants
Start Date 2022-10-31
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15